Maintaining higher dose

at follow-up visit

Dose escalation

at follow-up visit

Fesoterodine

156

Solifenacin

48

p value

Fesoterodine

194

Solifenacin

134

p value

Women, n (%)

235 (86.5)

40 (83.3)

NS

144 (74.2)

98 (73.1)

NS

Age, mean (SD), years

62.2 (12.3)

59.4 (13.7)

NS

61.4 (10.8)

60.8 (12.5)

NS

BMI, mean (SD), Kg/m2

26.0 (4.3)

25.5 (4.4)

NS

26.5 (3.6)

26.1 (3.7)

NS

OAB evolution time, mean (SD), months

14.5 (22.2)

17.9 (21.8)

NS

21.6 (69.0)

17.4 (21.6)

NS

Concomitant disease, mean (SD)

2.9 (2.6)

2.9 (2.5)

NS

3.3 (2.7)

3.4 (2.8)

NS

Concomitant disease, n (%)

128 (82.1)

37 (77.1)

NS

170 (87.6)

113 (84.3)

NS

Hypertension

63 (49.2)

11 (29.7)

0.040

85 (50.0)

64 (56.6)

NS

Cardiovascular disease

20 (15.6)

6 (11.1)

0.008

13 (7.6)

18 (15.9)

0.033

Urinary tract infections

62 (48.4)

16 (43.2)

NS

77 (45.3)

32 (28.3)

0.004

Mellitus diabetes

25 (19.5)

7 (18.9)

NS

32(18.8)

21 (18.5)

NS

Depression

35 (27.3)

9 (24.3)

NS

38 (22.3)

28 (24.7)

NS

Insomnia

42 (32.8)

12 (32.4)

NS

50 (29.4)

49 (43.4)

0.016

Obesity (BMI ≥ 30 Kg/m2)

29 (22.7)

6 (16.2)

NS

42 (24.7)

26 (23.0)

NS

Rheumatic disease

18 (14.1)

9 (24.3)

NS

36 (21.2)

28 (24.8)

NS

Fibromyalgia

2 (1.6)

3 (8.1)

NS

15 (8.8)

21 (18.6)

0.018

*BPH

16/21 (76.2)

3/8 (37.5)

NS

33/50 (66.0)

21/36 (58.3)

NS